CareDx CDNA 深 沪
已收盘 08-29 16:00:00 美东时间
13.66
+0.550
+4.20%
华盛通- 最 高13.7688
- 今 开13.17
- 成交量 203.22万股
- 最 低 13.06
- 昨 收 13.11
- 总市值 7.27亿
- 52周最高 32.97
- 市盈率 静 14.72
- 换手率 0.00%
- 52周最低 10.96
- 委 比 26.75%
- 总股本 5322.69万
- 历史最高 99.83
- 量 比 1.28
- 振 幅 5.41%
- 历史最低 0.76
- 每 手 1
- 风险率 8.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential
CareDx, Inc. faces uncertainty with proposed reimbursement changes, but has long-term potential in the $8 billion transplant solutions market.
08-27 01:08
William Blair Initiates Coverage On CareDx with Market Perform Rating
William Blair analyst Andrew Brackmann initiates coverage on CareDx (NASDAQ:CDNA) with a Market Perform rating.
08-26 19:32
中信建投：国产芯片今年将迎来发展大年
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 中信建投证券研究 国产算力板块迎来密集催化，腾讯业绩会表示推理芯...
08-26 07:27
Cathie Wood Pounces On Peter Thiel-Backed Bullish Stock After Wild IPO Surge: Ark Buys Stock Worth $172.22 Million
Ark Invest, led by Cathie Wood, made big trades in Bullish and Shopify. They bought over 2.5 million shares of Bullish and sold over $3 million of Shopify stock.
08-14 09:46
A Look Ahead: Stoke Therapeutics's Earnings Forecast
Stoke Therapeutics (NASDAQ:STOK) is preparing to release its quarterly earnings...
08-12 00:03
CareDx appoints new CFO
CareDx (NASDAQ:CDNA) has appointed Nathan Smith as its new chief financial officer. Smith brings over 14 years of experience in molecular diagnostics, including senior roles at Myriad Genetics, Blackr...
08-07 06:53
CareDx Appoints New CFO Amid Financial Growth
CareDx ( ($CDNA) ) has issued an update. CareDx announced the appointment of Na...
08-07 04:49
CareDx Narrows FY2025 Sales Guidance from $365.000M-$375.000M to $367.000M-$373.000M vs $370.794M Est
CareDx (NASDAQ:CDNA) narrows FY2025 sales outlook from $365.000 million-$375.000 million to $367.000 million-$373.000 million vs $370.794 million estimate.
08-07 04:37
CareDx Publishes KOAR Study In American Journal of Transplantation, Showcasing AlloSure dd-cfDNA For Enhanced Kidney Rejection Detection And Biopsy Guidance
KOAR, the Largest Prospective Study of Its Kind, Demonstrates Clinical Utility of AlloSure® in Kidney Transplant SurveillanceAlloSure Kidney dd-cfDNA Elevation Strongly Predicts Rejection and Improves Biopsy
08-07 01:09
